Clinical trial

The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density

NCT04630964

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2021-01-01

PhasePHASE2

Study timeline

Study start (actual)2021-01-01Date precision: day

Registry last updated2024-04-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Major Depressive Disorderunresolved

Depressionunresolved

Interventions

PsilocybinDRUG

NiacinDRUG · verified · RxNorm: niacin

Sponsors & collaborators

Section for Affective Disorders; Northern Stockholm Psychiatrylead sponsor

Karolinska Institutetcollaborator

Mapped research locations

StockholmSweden1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04630964 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.